The Market Reports

Synopsis
The global market for Liquid Biopsy Products was estimated to be worth US$ 5142 million in 2024 and is forecast to a readjusted size of US$ 11449 million by 2031 with a CAGR of 12.4% during the forecast period 2025-2031.

Liquid biopsy products refer to a category of in vitro diagnostic tools that non-invasively analyze biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood, urine, or other body fluids for cancer screening, diagnosis, treatment monitoring, and recurrence prediction. These products span key steps such as sample collection, preservation, nucleic acid extraction, target detection, and data interpretation. Compared to traditional tissue biopsy, liquid biopsy offers advantages in safety, repeatability, and applicability across various cancer types, making it increasingly adopted in clinical settings and showing great potential in precision and personalized medicine.

The rapid global advancement of precision medicine and rising cancer incidence form a strong foundation for liquid biopsy adoption. National healthcare systems are increasingly incorporating liquid biopsy into cancer screening and targeted therapy workflows. The declining cost of next-generation sequencing (NGS) and enhanced interpretation capabilities through AI are accelerating product entry into multi-cancer detection and multicenter clinical validation.

Despite increasing technological maturity, liquid biopsy still faces challenges in balancing sensitivity and specificity, especially for early-stage cancer detection. Non-uniform standards in sample processing and reagent quality across upstream and downstream components complicate clinical translation.

Regulatory hurdles around privacy and bioethics remain significant barriers for global expansion. Broker analyses highlight that most revenue still stems from research-grade orders, and wider clinical adoption and reimbursement pathways require further development.

Demand for liquid biopsy is rapidly shifting from research use to routine clinical applications. Monitoring therapeutic response and early relapse detection in high-incidence cancers—such as lung, breast, and colorectal—are driving hospital procurement. Collaboration between biotech companies and hospitals is deepening, with joint labs and multicenter studies becoming the norm. Annual reports also reflect growing patient awareness and preference for non-invasive testing, spurring product expansion into home-testing and mobile diagnostic scenarios.

This report aims to provide a comprehensive presentation of the global market for Liquid Biopsy Products, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Liquid Biopsy Products by region & country, by Type, and by Application.

The Liquid Biopsy Products market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liquid Biopsy Products.

Market Segmentation

By Company

• Roche
• Illumina
• Qiagen
• Guardant Health
• MDxHealth
• Pathway Genomics
• NeoGenomics Laboraories
• Novogen
• BGI
• Myriad Genetics
• Adaptive Biotechnologies
• Biocept
• Angle plc
• Exact Sciences
• Natera
• Freenome
• Aide Bio
• Thermo Fisher Scientific

Segment by Type

• CTCs
• ctDNA
• Exosomes

Segment by Sample

• Blood Sample
• Urine Sample
• Other

Segment by Application

• Hospitals and Clinics
• Third-party Laboratories
• Other

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.